|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Immunotherapy in Oncology: Gaining Momentum
The immunotherapy field in cancer has never been more potent than it is right now, including block buster drugs like Avastin, Erbitux, and Rituxan. Antibodies are making the headlines but cancer vaccines are not far away. The recent approval of Gardas
The Commercial Success of Cancer Therapeutic Antibodies
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeut
Monoclonal Antibody Therapies: Sector Analysis Tool
The monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004. It has the potential to triple in value over the next six years and reach $30.
Cancer Vaccines: Drug Pipeline Update 2008
There are today more than 235 cancer vaccines, from early preclinical to marketed drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 91 different targets. Th
Triple Analysis: Melanoma, Antibodies and Vaccines in Oncology
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Melanoma Therapeutics, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This
Results 1 - 11 of 11
|
Latest News
|
Expert Views: Are the US and emerging markets ready for the generic drug boom? |
|
Read more...
|
|
Expert Views: Cytotoxic therapies to feel sting of generics |
|
Read more...
|
|
Expert Views: Hope for Obama's healthcare IT plan |
|
Read more...
|
|
|
